Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Bone Marrow Transplant. 2011 Feb 28;47(1):65–72. doi: 10.1038/bmt.2011.16

Figure 2. Outcomes stratified by histology.

Figure 2

All curves are stratified for histology: CTCL (n=11) versus Others (n=16), with a median follow-up of 83 months for the 5 CTCL surviving patients and 36 months for the 9 Others. P-values for long-rank comparisonof curves is given in the bottom right hand corner of each graph. Panel A shows the Kaplan-Meier estimate of survival probability. Panel B shows progression-free survival, defined as time from stem cell infusion to recurrence, progression, or death from any cause, whichever occurred first. Panel C shows cumulative incidence of relapse/progression, defined as time from stem cell infusion to recurrence or progression. Panel D shows non-relapse mortality, measured as time from stem cell infusion to death from any cause other than disease relapse or disease progression. For data in panels C and D, relapse/progression and non-relapse mortality were treated as competing risks.